Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and Industry Forecast, 2017-2023
The global diabetes therapeutics market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Diabetes therapeutics are drugs used by diabetic patients to restore the blood glucose metabolism to a normal state.
The factors that drive the global diabetes therapeutics market include rise in geriatric population, increase in prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government However, side effects of diabetic drugs and stringent approval process for the same restrict the market growth. Moreover, surge in awareness about diabetes care and market potential in developing regions are expected to provide numerous opportunities for market growth.
The global diabetes therapeutics market is segmented on the basis of product and region. Based on product, it is bifurcated into injectable and oral-antidiabetic drugs (OAD). Injectable are further categorized into insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, and amylinomimetic drug. Oral-antidiabetic drugs (OAD) segment is further divided into biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, meglitinides, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
BY PRODUCT
The factors that drive the global diabetes therapeutics market include rise in geriatric population, increase in prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government However, side effects of diabetic drugs and stringent approval process for the same restrict the market growth. Moreover, surge in awareness about diabetes care and market potential in developing regions are expected to provide numerous opportunities for market growth.
The global diabetes therapeutics market is segmented on the basis of product and region. Based on product, it is bifurcated into injectable and oral-antidiabetic drugs (OAD). Injectable are further categorized into insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, and amylinomimetic drug. Oral-antidiabetic drugs (OAD) segment is further divided into biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, meglitinides, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
- Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.
BY PRODUCT
- Injectables
- Insulin
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics
- Amylin Analogue/Amylinomimetic Drugs
- Oral-antidiabetic Drugs (OAD)
- Biguanides
- Sulfonylureas
- Thiazolidinediones
- Alpha-glucosidase Inhibitors
- Dipeptidyl Peptidase IV (DPP-4) Inhibitors/Gliptins
- Meglitinides
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors/Gliflozins
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- Eli Lilly and Company
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Biocon Limited
- Diasome Pharmaceuticals, Inc.
- Generex Biotechnology Corp.
- MannKind Corporation
- Pfizer Inc.
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Competitive intelligence of companies and their strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
CHAPTER 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. INJECTABLES
4.2.1. Insulin
4.2.1.1. Market size and forecast
4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists
4.2.2.1. Market size and forecast
4.2.3. Amylinomimetic drug
4.2.3.1. Market size and forecast
4.2.4. Key market trends
4.2.5. Growth factors and opportunities
4.2.6. Market size and forecast
4.3. ORAL-ANTIDIABETIC DRUGS (OAD)
4.3.1. Biguanides
4.3.1.1. Market size and forecast
4.3.2. Sulfonylureas
4.3.2.1. Market size and forecast
4.3.3. Thiazolidinediones
4.3.3.1. Market size and forecast
4.3.4. Alpha-glucosidase inhibitors
4.3.4.1. Market size and forecast
4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors
4.3.5.1. Market size and forecast
4.3.6. Meglitinides
4.3.6.1. Market size and forecast
4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
4.3.7.1. Market size and forecast
4.3.8. Key market trends
4.3.9. Growth factors and opportunities
4.3.10. Market size and forecast
CHAPTER 5 DIABETES THERAPEUTICS MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. Australia
5.4.8. South Korea
5.4.9. Rest of Asia-Pacific
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA
CHAPTER 6 COMPANY PROFILES
6.1. ASTRAZENECA PLC
6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments
6.2. BOEHRINGER INGELHEIM GMBH
6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments
6.3. ELI LILLY AND COMPANY
6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Key strategic moves and developments
6.4. GLAXOSMITHKLINE PLC
6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments
6.5. JOHNSON & JOHNSON
6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments
6.6. MERCK & CO., INC.
6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments
6.7. NOVARTIS AG
6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments
6.8. NOVO NORDISK
6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments
6.9. SANOFI S.A.
6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments
6.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Competitive intelligence of companies and their strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
CHAPTER 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. INJECTABLES
4.2.1. Insulin
4.2.1.1. Market size and forecast
4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists
4.2.2.1. Market size and forecast
4.2.3. Amylinomimetic drug
4.2.3.1. Market size and forecast
4.2.4. Key market trends
4.2.5. Growth factors and opportunities
4.2.6. Market size and forecast
4.3. ORAL-ANTIDIABETIC DRUGS (OAD)
4.3.1. Biguanides
4.3.1.1. Market size and forecast
4.3.2. Sulfonylureas
4.3.2.1. Market size and forecast
4.3.3. Thiazolidinediones
4.3.3.1. Market size and forecast
4.3.4. Alpha-glucosidase inhibitors
4.3.4.1. Market size and forecast
4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors
4.3.5.1. Market size and forecast
4.3.6. Meglitinides
4.3.6.1. Market size and forecast
4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
4.3.7.1. Market size and forecast
4.3.8. Key market trends
4.3.9. Growth factors and opportunities
4.3.10. Market size and forecast
CHAPTER 5 DIABETES THERAPEUTICS MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. Australia
5.4.8. South Korea
5.4.9. Rest of Asia-Pacific
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA
CHAPTER 6 COMPANY PROFILES
6.1. ASTRAZENECA PLC
6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments
6.2. BOEHRINGER INGELHEIM GMBH
6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments
6.3. ELI LILLY AND COMPANY
6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Key strategic moves and developments
6.4. GLAXOSMITHKLINE PLC
6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments
6.5. JOHNSON & JOHNSON
6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments
6.6. MERCK & CO., INC.
6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments
6.7. NOVARTIS AG
6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments
6.8. NOVO NORDISK
6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments
6.9. SANOFI S.A.
6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments
6.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 2. GLOBAL INJECTABLE DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 3. DIABETES INJECTABLE THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 5. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 9. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 10. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 11. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 12. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 13. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 14. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 15. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 16. BOEHRINGER: COMPANY SNAPSHOT
TABLE 17. ELI LILLY: COMPANY SNAPSHOT
TABLE 18. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 19. J&J: COMPANY SNAPSHOT
TABLE 20. MERCK: COMPANY SNAPSHOT
TABLE 21. NOVARTIS: COMPANY SNAPSHOT
TABLE 22. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 23. SANOFI: COMPANY SNAPSHOT
TABLE 24. TAKEDA: COMPANY SNAPSHOT
TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 2. GLOBAL INJECTABLE DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 3. DIABETES INJECTABLE THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 5. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 9. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 10. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 11. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 12. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 13. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 14. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 15. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 16. BOEHRINGER: COMPANY SNAPSHOT
TABLE 17. ELI LILLY: COMPANY SNAPSHOT
TABLE 18. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 19. J&J: COMPANY SNAPSHOT
TABLE 20. MERCK: COMPANY SNAPSHOT
TABLE 21. NOVARTIS: COMPANY SNAPSHOT
TABLE 22. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 23. SANOFI: COMPANY SNAPSHOT
TABLE 24. TAKEDA: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 1. DIABETES THERAPEUTICS MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 8. MARKET SHARE ANALYSIS, DIABETES THERAPEUTICS MARKET, 2016
FIGURE 9. IMPACT ANALYSIS: DIABETES THERAPEUTICS MARKET
FIGURE 10. TOTAL NUMBER OF CLINICAL TRIALS IN DIABETES THERAPEUTICS MARKET
FIGURE 11. INSULIN MARKET, 2016-2023, ($MILLION)
FIGURE 12. GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS/INCRETIN MIMETICS MARKET, 2016-2023, ($MILLION)
FIGURE 13. AMYLIN ANALOGUE/AMYLINOMIMETIC DRUG MARKET, 2016-2023, ($MILLION)
FIGURE 14. BIGUANIDES MARKET, 2016-2023, ($MILLION)
FIGURE 15. SULFONYLUREAS MARKET, 2016-2023, ($MILLION)
FIGURE 16. THIAZOLIDINEDIONES MARKET, 2016-2023, ($MILLION)
FIGURE 17. ALPHA-GLUCOSIDASE INHIBITORS MARKET, 2016-2023, ($MILLION)
FIGURE 18. DIPEPTIDYL PEPTIDASE IV (DPP-4) INHIBITORS /GLIPTINS MARKET, 2016-2023, ($MILLION)
FIGURE 19. MEGLITINIDES MARKET, 2016-2023, ($MILLION)
FIGURE 20. SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS /GLIFLOZINS MARKET, 2016-2023, ($MILLION)
FIGURE 21. U.S. DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 22. CANADA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 23. MEXICO DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 24. GERMANY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 25. FRANCE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 26. UK DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 27. ITALY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 28. SPAIN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 29. REST OF EUROPE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 30. JAPAN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 31. CHINA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 32. INDIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 33. AUSTRALIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 34. SOUTH KOREA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 36. BRAZIL DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 37. SOUTH AFRICA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 38. SAUDI ARABIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 39. REST OF LAMEA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 1. DIABETES THERAPEUTICS MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 8. MARKET SHARE ANALYSIS, DIABETES THERAPEUTICS MARKET, 2016
FIGURE 9. IMPACT ANALYSIS: DIABETES THERAPEUTICS MARKET
FIGURE 10. TOTAL NUMBER OF CLINICAL TRIALS IN DIABETES THERAPEUTICS MARKET
FIGURE 11. INSULIN MARKET, 2016-2023, ($MILLION)
FIGURE 12. GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS/INCRETIN MIMETICS MARKET, 2016-2023, ($MILLION)
FIGURE 13. AMYLIN ANALOGUE/AMYLINOMIMETIC DRUG MARKET, 2016-2023, ($MILLION)
FIGURE 14. BIGUANIDES MARKET, 2016-2023, ($MILLION)
FIGURE 15. SULFONYLUREAS MARKET, 2016-2023, ($MILLION)
FIGURE 16. THIAZOLIDINEDIONES MARKET, 2016-2023, ($MILLION)
FIGURE 17. ALPHA-GLUCOSIDASE INHIBITORS MARKET, 2016-2023, ($MILLION)
FIGURE 18. DIPEPTIDYL PEPTIDASE IV (DPP-4) INHIBITORS /GLIPTINS MARKET, 2016-2023, ($MILLION)
FIGURE 19. MEGLITINIDES MARKET, 2016-2023, ($MILLION)
FIGURE 20. SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS /GLIFLOZINS MARKET, 2016-2023, ($MILLION)
FIGURE 21. U.S. DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 22. CANADA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 23. MEXICO DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 24. GERMANY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 25. FRANCE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 26. UK DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 27. ITALY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 28. SPAIN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 29. REST OF EUROPE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 30. JAPAN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 31. CHINA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 32. INDIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 33. AUSTRALIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 34. SOUTH KOREA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 36. BRAZIL DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 37. SOUTH AFRICA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 38. SAUDI ARABIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 39. REST OF LAMEA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
